Article

Amersham, Galil announce joint agreement

Amersham and Galil Medical announced an agreement to merge portions oftheir respective buinesses into a new yet-unnamed venture.

Related Videos
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, highlights recent advances in kidney stone technology
Ian Metzler, MD, highlights recent advances in kidney stone technology
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Sima Porten, MD, on gene-environment interactions in bladder cancer development
1 expert in this video
Resective Surgery and Minimally Invasive Procedures For BPH
Naeem Bhojani, MD, expands on key findings from WATER III trial
Naeem Bhojani, MD, expands on key findings from WATER III trial
Hailey Frye answers a question during a Zoom video interview
Hailey Frye discusses improvement of pain management for nephrolithiasis
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
1 expert is featured in this series.
Key Limitations of MAIC Analyses
1 expert is featured in this series.
Matching-Adjusted Indirect Comparisons in mHSPC
Related Content
Gene variant associated with increased risk of BPH
April 16th 2025

Gene variant associated with increased risk of BPH

Hannah Clarke
Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
3d rendered medically accurate illustration of prostate cancer | Image Credit: @ Sebastian Kaulitzki - stock.adobe.com
April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke
The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Man holding smartphone | Image Credit: © ARAMYAN - stock.adobe.com
April 15th 2025

App shows promise in managing lower urinary tract symptoms

Christian Gratzke, MD Benjamin P. Saylor
Christian Gratzke, MD, explains why an app shows promise for patients with lower urinary tract symptoms.
Study underway to assess 3-fraction SBRT regimen in prostate cancer
April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke
"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
© 2025 MJH Life Sciences

All rights reserved.